ALS progresses very unevenly, with some patients declining quickly while others live considerably longer, which makes early prediction hard. A collaboration between researchers in Sweden, Japan and Italy set out to test whether the Alzheimer's-related changes that sometimes coexist with ALS in the brain affect how the disease unfolds.
The team measured amyloid beta in the cerebrospinal fluid of 264 Japanese patients with ALS, comparing them with 164 people who had other neurological diseases. Amyloid beta is used as a biomarker of changes associated with Alzheimer's disease. The researchers reported that about 14 per cent of the ALS patients showed signs of these changes.
The more striking result concerned neurofilament light chain (NfL), a marker of nerve cell damage. The study found that whether amyloid beta-related changes were present altered what high NfL levels meant. In the amyloid beta-positive group, high NfL was linked to shorter survival more strongly than in the amyloid beta-negative group. Data from 153 patients in Bologna, Italy, supported the pattern, and the researchers also saw an interaction between amyloid beta and NfL in relation to decline in everyday physical function. The authors suggest that the same NfL level may carry different prognostic meaning depending on what else is happening in the brain, though the underlying mechanisms have not been established.
The team also tested machine-learning models that combined NfL with other biomarkers, including amyloid beta. These improved identification of ALS, including in people whose NfL values fell in a borderline range. The researchers envision NfL serving as a first-line assessment, with additional biomarkers and a detailed clinical examination used when results are unclear. Better prognostic information could also help clinicians talk with patients and families about what to expect, and could help clinical trials group participants with similar expected disease courses, making it easier to judge whether a treatment works.
The authors are clear about the limits. The study is based on observational data, the findings cannot yet guide clinical decisions, and the methods need confirmation in further independent patient groups. The researchers plan to examine whether biomarkers linked to other neurodegenerative conditions, such as Parkinson's disease, also affect ALS prognosis.